Evaxion to present at World Vaccine Congress
Rhea-AI Summary
Evaxion Biotech (NASDAQ: EVAX), a clinical-stage TechBio company, will showcase its AI-Immunology™ platform at the World Vaccine Congress in Washington, D.C., from April 21-24, 2025. The company will deliver two key presentations and host booth #351.
Chief Scientific Officer Birgitte Rønø will present on AI-powered antigen target discovery for cancer vaccines on April 23 at 11:40 ET in Room 206. Additionally, Pär Comstedt, VP of Infectious Disease Vaccine Development, will discuss AI-powered target discovery for infectious disease vaccines at 15:10 ET in Room 202b.
This congress marks one of several scientific, partnering, and investor conferences where Evaxion plans to engage with potential partners and collaborators in Q2 2025. The company will demonstrate its AI-Immunology™ platform's capabilities in vaccine development for both cancers and infectious diseases.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, EVAX gained 1.50%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
- Congress will take place April 21-24, 2025, in Washington, D.C.
COPENHAGEN, Denmark, April 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will give two presentations and man a booth at the World Vaccine Congress taking place April 21-24, 2025, in Washington, D.C.
Birgitte Rønø, Chief Scientific Officer at Evaxion, will talk about the application of Evaxion’s AI-Immunology™ platform for antigen target discovery for cancer vaccines. Pär Comstedt, Vice President, Infectious Disease Vaccine Development at Evaxion, will present the use of AI-Immunology™ for target discovery for infectious disease vaccines. See details on the presentations below.
The World Vaccine Congress is just one of several scientific, partnering and investor conferences where Evaxion will profile itself and discuss with potential partners and collaborators in the second quarter of 2025.
Throughout the conference, Evaxion invites interested parties to its booth #351 for discussions on effective and accurate target discovery with AI-Immunology™ as well as our pipeline of vaccine candidates for cancers and infectious diseases.
Presentation details:
| Title: | AI-powered antigen target discovery for cancer vaccines |
| Category: | Cancer immunotherapy |
| Location: | Room 206 |
| Date/Time: | April 23, 2025, at 11.40 ET/17.40 CET |
| Presenter: | Birgitte Rønø, Chief Scientific Officer at Evaxion |
| Title: | AI-powered target discovery for infectious disease vaccines |
| Category: | Emerging and re-emerging diseases |
| Location: | Room 202b |
| Date/Time: | April 23, 2025, at 15.10 ET/21.10 CET |
| Presenter: | Pär Comstedt, VP, Infectious Disease Vaccine Development at Evaxion |
Contact information
Evaxion Biotech A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
About EVAXION
Evaxion Biotech A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
What presentations will Evaxion (EVAX) give at the 2025 World Vaccine Congress?
Where can investors meet Evaxion (EVAX) representatives at the World Vaccine Congress 2025?
What technology will Evaxion (EVAX) showcase at the 2025 World Vaccine Congress?
What is Evaxion's (EVAX) conference strategy for Q2 2025?
